Opioid Receptor Antagonism Attenuates Antidepressant Effects of Ketamine methods
Aim. Evidence-backed execution summary for Opioid Receptor Antagonism Attenuates Antidepressant Effects of Ketamine methods from Opioid Receptor Antagonism Attenuates Antidepressant Effects of Ketamine.
Show snapshot details
On this page
This experiment, in seven questions
Jump straight to the part of the recipe you need. Data and provenance labels stay close to the action they support.
Shopping and prep list
What do I need before I start?
human
Subject model for the experiment.
- Use
- confirm full cohort details in the source paper
Methods
reagent used in the protocol.
- Use
- All eligible participants provided full written informed consent. The study protocol was approved by the Stanford University Institutional Review Board. All participants were required to hold any stimulant/amphetamine drugs documented during the screening phase for the 24 hours prior to ketamine administration and c...
Discussion
There are a number of strengths and weaknesses in our study. A cross-over study was the optimal method to test the study's mechanistic hypothesis, since it can clearly identify ketamine responders post-hoc and establish, in an individual participant, that ketamine's antidepressant effects are mediated vi...
- Use
- There are a number of strengths and weaknesses in our study. A cross-over study was the optimal method to test the study's mechanistic hypothesis, since it can clearly identify ketamine responders post-hoc and establish, in an individual participant, that ketamine's antidepressant effects are mediated vi...
Before you run
What should be confirmed before execution?
First confirmation
Equipment is listed but no product mappings are linked.
Confirm before execution
This page is backed by a publishable Replication Data Ledger package with zero critical source-verification issues.
Confirm before execution
Open the source paper before finalizing run-specific details.
Procurement checkpoint
Use source-stated vendors where present. Treat mapped products as sourcing options unless the page marks an exact source match.
Open quote workflowStep-by-step procedure
What do I do, in order?
Methods:
In a proposed double-blind, cross-over study of 30 adults with treatment-resistant depression, we performed a planned interim analysis after studying 14 participants, 12 of whom completed both conditions in randomized order: 50mg naltrexone preceding 0.5mg/kg ketamine or placebo preceding 0.5mg/kg ketamine.
Methods
Potential study participants were brought into the clinic for a screening visit to determine eligibility. All study participants were outpatients. Inclusion criteria included a current diagnosis of a non-psychotic, non-atypical major depressive episode as part of either bipolar II disorder or major depressive disorder, defined by DSM-5 criteria ( ). For the initial enrollment, all participants were required to have a score ≥20 on the 17-item Hamilton Depression Rating Scale ( ). Each participant was also required to have not benefited sufficiently from trials of at least 4 different antidepressant medications or other somatic treatments as defined by the Massachusetts General Hospital Antidepressant Treatment History Questionnaire criteria ( ), as well as a minimum of 6 weeks of prior psychotherapy during any major depressive episode prior to intervention.
Methods
All eligible participants provided full written informed consent. The study protocol was approved by the Stanford University Institutional Review Board. All participants were required to hold any stimulant/amphetamine drugs documented during the screening phase for the 24 hours prior to ketamine administration and could resume these medications Day 1 post-infusion after the completion of the ratings. Participants were required to withhold taking any benzodiazepine for the 8 hours prior to (or any hypnotic drugs the night prior to) ketamine administration and could resume these medications Day 1 post-infusion after the completion of the ratings. Furthermore, any medical marijuana use was held for two weeks in order to allow for proper washout prior to the baseline/randomization visit (e.g., at least 5 half-lives of the drug). We excluded individuals on opiates in order to avoid naltrex...
Measurement outputs
What raw and processed outputs should exist?
In a proposed double-blind, cross-over study of 30 adults with treatment-resistant depression, we performed a planned interim analysis after studying 14 participants, 12 of whom...
- Raw artifact
- Per-sample or per-animal endpoint measurements collected during the experiment
- Processed artifact
- Structured table with cleaned measurements ready for comparison
- Reported as
- Summary statistics and between-group or across-timepoint comparisons
Potential study participants were brought into the clinic for a screening visit to determine eligibility. All study participants were outpatients. Inclusion criteria included a...
- Raw artifact
- Per-sample or per-animal endpoint measurements collected during the experiment
- Processed artifact
- Structured table with cleaned measurements ready for comparison
- Reported as
- Summary statistics and between-group or across-timepoint comparisons
There are a number of strengths and weaknesses in our study. A cross-over study was the optimal method to test the study's mechanistic hypothesis, since it can clearly ide...
- Raw artifact
- Per-sample or per-animal endpoint measurements collected during the experiment
- Processed artifact
- Structured table with cleaned measurements ready for comparison
- Reported as
- Summary statistics and between-group or across-timepoint comparisons
Analysis plan
How should the outputs become interpretable results?
Acquisition
Collect raw experimental outputs with enough metadata to preserve sample identity, condition, and timing.
inferred from protocolPreprocessing / cleaning
There are a number of strengths and weaknesses in our study.
from paperScoring or quantification
Quantify the primary readouts for this experiment: In a proposed double-blind, cross-over study of 30 adults with treatment-resistant depression, we performed a planned interim analysis after studying 14 participants, 12 of whom...; Potential study participants were brought into the clinic for a screening visit to determine eligibility. All study participants were outpatients. Inclusion criteria included a...; There are a number of strengths and weaknesses in our study. A cross-over study was the optimal method to test the study's mechanistic hypothesis, since it can clearly ide....
from paperStatistical comparison
There are a number of strengths and weaknesses in our study. A cross-over study was the optimal method to test the study's mechanistic hypothesis, since it can clearly ide...
from paperReporting output
Report representative outputs alongside summary comparisons for In a proposed double-blind, cross-over study of 30 adults with treatment-resistant depression, we performed a planned interim analysis after studying 14 participants, 12 of whom..., Potential study participants were brought into the clinic for a screening visit to determine eligibility. All study participants were outpatients. Inclusion criteria included a..., There are a number of strengths and weaknesses in our study. A cross-over study was the optimal method to test the study's mechanistic hypothesis, since it can clearly ide....
inferred from protocolStructured statistical methods
There are a number of strengths and weaknesses in our study. A cross-over study was the optimal method to test the study's mechanistic hypothesis, since it can clearly ide...
source structuredSource and audit
What supports the facts on this page?
Evidence quotes (3)
In a proposed double-blind, cross-over study of 30 adults with treatment-resistant depression, we performed a planned interim analysis after studying 14 participants, 12 of whom completed both conditions in randomized order: 50mg naltrexone preceding 0.5mg/kg ketamine or placebo preceding 0.5mg/kg ketamine.
Potential study participants were brought into the clinic for a screening visit to determine eligibility. All study participants were outpatients. Inclusion criteria included a current diagnosis of a non-psychotic, non-atypical major depressive episode as part of either bipolar II disorder or major depressive disorder, defined by DSM-5 criteria ( ). For the initial enrollment, all participants were required to have a score ≥20 on the 17-item Hamilton Depression Rating Scale ( ). Each participant was also required to have not benefited sufficiently from trials of at least 4 different antidepressant medications or other somatic treatments as defined by the Massachusetts General Hospital Antidepressant Treatment History Questionnaire criteria ( ), as well as a minimum of 6 weeks of prior psychotherapy during any major depressive episode prior to intervention.
All eligible participants provided full written informed consent. The study protocol was approved by the Stanford University Institutional Review Board. All participants were required to hold any stimulant/amphetamine drugs documented during the screening phase for the 24 hours prior to ketamine administration and could resume these medications Day 1 post-infusion after the completion of the ratings. Participants were required to withhold taking any benzodiazepine for the 8 hours prior to (or any hypnotic drugs the night prior to) ketamine administration and could resume these medications Day 1 post-infusion after the completion of the ratings. Furthermore, any medical marijuana use was held for two weeks in order to allow for proper washout prior to the baseline/randomization visit (e.g., at least 5 half-lives of the drug). We excluded individuals on opiates in order to avoid naltrexone precipitating opioid withdrawal along with eliminating the confound of ketamine-opioid interactions. If a washout period was necessary prior to study participation, the study physician maintained ongoing contact with the participant to ensure safety during this time. Those medications deemed lik...
Machine-readable layer
[
{
"@context": "https://schema.org",
"@type": "HowTo",
"name": "Opioid Receptor Antagonism Attenuates Antidepressant Effects of Ketamine methods",
"description": "Evidence-backed execution summary for Opioid Receptor Antagonism Attenuates Antidepressant Effects of Ketamine methods from Opioid Receptor Antagonism Attenuates Antidepressant Effects of Ketamine.",
"totalTime": "PT15840M",
"step": [
{
"@type": "HowToStep",
"position": 1,
"name": "Methods:",
"text": "In a proposed double-blind, cross-over study of 30 adults with treatment-resistant depression, we performed a planned interim analysis after studying 14 participants, 12 of whom completed both conditions in randomized order: 50mg naltrexone preceding 0.5mg/kg ketamine or placebo preceding 0.5mg/kg ketamine."
},
{
"@type": "HowToStep",
"position": 2,
"name": "Methods",
"text": "Potential study participants were brought into the clinic for a screening visit to determine eligibility. All study participants were outpatients. Inclusion criteria included a current diagnosis of a non-psychotic, non-atypical major depressive episode as part of either bipolar II disorder or major depressive disorder, defined by DSM-5 criteria ( ). For the initial enrollment, all participants were required to have a score ≥20 on the 17-item Hamilton Depression Rating Scale ( ). Each participant was also required to have not benefited sufficiently from trials of at least 4 different antidepressant medications or other somatic treatments as defined by the Massachusetts General Hospital Antidepressant Treatment History Questionnaire criteria ( ), as well as a minimum of 6 weeks of prior psychotherapy during any major depressive episode prior to intervention."
},
{
"@type": "HowToStep",
"position": 3,
"name": "Methods",
"text": "All eligible participants provided full written informed consent. The study protocol was approved by the Stanford University Institutional Review Board. All participants were required to hold any stimulant/amphetamine drugs documented during the screening phase for the 24 hours prior to ketamine administration and could resume these medications Day 1 post-infusion after the completion of the ratings. Participants were required to withhold taking any benzodiazepine for the 8 hours prior to (or any hypnotic drugs the night prior to) ketamine administration and could resume these medications Day 1 post-infusion after the completion of the ratings. Furthermore, any medical marijuana use was held for two weeks in order to allow for proper washout prior to the baseline/randomization visit (e.g., at least 5 half-lives of the drug). We excluded individuals on opiates in order to avoid naltrex..."
}
],
"tool": [
{
"@type": "HowToTool",
"name": "Discussion"
}
],
"supply": [
{
"@type": "HowToSupply",
"name": "Methods"
}
],
"isBasedOn": {
"@type": "ScholarlyArticle",
"headline": "Opioid Receptor Antagonism Attenuates Antidepressant Effects of Ketamine",
"datePublished": "2018",
"author": [
{
"@type": "Person",
"name": "Nolan R. Williams"
},
{
"@type": "Person",
"name": "Boris D. Heifets"
},
{
"@type": "Person",
"name": "Christine Blasey"
},
{
"@type": "Person",
"name": "Keith Sudheimer"
},
{
"@type": "Person",
"name": "Jaspreet Pannu"
},
{
"@type": "Person",
"name": "Heather Pankow"
},
{
"@type": "Person",
"name": "Jessica Hawkins"
},
{
"@type": "Person",
"name": "Justin Birnbaum"
},
{
"@type": "Person",
"name": "David M. Lyons"
},
{
"@type": "Person",
"name": "Carolyn I. Rodriguez"
},
{
"@type": "Person",
"name": "Alan F. Schatzberg"
}
],
"identifier": "10.1176/appi.ajp.2018.18020138"
}
},
{
"@context": "https://schema.org",
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Experiments",
"item": "https://replicatescience.com/experiments"
},
{
"@type": "ListItem",
"position": 2,
"name": "Opioid Receptor Antagonism Attenuates Antidepressant Effects of Ketamine methods",
"item": "https://replicatescience.com/experiments/opioid-receptor-antagonism-attenuates-antidepressant-effects-of-ketamine-methods-nolan-r-williams-pmc6395554/attenuation-of-antidepressant-effects-of-ketamine-by-opioid-receptor-antagonism-mlpgxywk"
}
]
}
]